Tips to prevent insect-borne diseases and protect yourself
CLAY COUNTY, Ind. (WTWO/WAWV) — As the weather in the valley warms up more and more bugs are starting to come back out. These pesky insects can irritate and infect unsuspecting people and animals.
Health officials WTWO/WAWV spoke with said these insects can do a lot more than just bug you, they are also capable of causing harm to your overall health by spreading dangerous diseases.
'The three of those biggest being Alpha-Gal, Lime Disease is really taking a large number climb up and then we're also seeing West Nile Virus later in the summertime but that could occur at any time,' said Carrico.
To avoid these diseases, Carrico said prevention is key.
'Depending on what you're doing, it's kind of a know-before-you-go. What kind of area, what kind of activities are you going to be doing, on how best to prepare. If you are out and you're going to be hiking in any kind of wooded or grassy area, make sure you're preventing from ticks. If you're going to be out between dusk or dawn, that is the most active time for mosquitoes,' said Carrico.
If you do end up getting bit by one of these insects, Health Educator at the Sullivan County Health Department, Rose Shepler said, to stay aware of the bite and monitor it for nearly a month.
'Definitely go see your primary care physician if you are experiencing symptoms. If you have a tick bite, you're going to want to monitor that for 30 days. If you have an unexplained rash or those flu-like symptoms you're going to want to see your primary care physician,' said Shepler.
Shepler and Carrico both said to also monitor your kids as they start to run around and enjoy the fun outside.
'You want to watch your kids, just this past weekend I pulled a tick off my 6-year-old, so when you come in for the evening take a look, check everyone for ticks,' said Shepler.
'Making sure that you're checking when they come inside every single time. If you have pets in the yard, you are still going to want to check your kids even if they haven't been outside a lot because we don't want a hitchhiker to latch on,' said Carrico.
Health officials also said the most common place to check for these insect bites are on the scalp, armpits and even between your toes as some ticks can be the size of the tip of a pencil.
If you want to know what diseases are most common in your area, Carrico recommends going to the Indiana Department of Health's tick and mosquito dashboard.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 days ago
- CBS News
First batch of West Nile-positive mosquitoes found in Chicago, health officials say
The Chicago Department of Public Health announced on Friday that the first batch of mosquitoes that tested positive for the West Nile virus were found in the city. This comes after other batches tested positive for the virus in Glenview and in McHenry and DuPage counties. The Illinois Department of Public Health confirmed the first positive batch in the state on May 13. However, no human cases have been reported in Illinois so far this year. What is West Nile virus? How to prevent it. West Nile virus is spread to people from infected mosquitoes, most commonly in the summer. Eight out of 10 people infected do not develop symptoms, according to the Centers for Disease Control and Prevention. The public is advised to do their best to protect themselves from mosquito bites, including using an EPA-registered insect repellent, wearing loose-fitting clothing, and, if possible, avoiding peak mosquito feeding times, typically around dusk and dawn. "As the weather gets warmer, all Chicago residents are encouraged to Fight the Bite and protect themselves against mosquito bites so they can remain safe and healthy this summer," CDPH Commissioner Dr. Olusimbo Ige said. It is also encouraged to check often overlooked places that may contain water, such as bird baths, water pails, and flower pots. What are the symptoms of West Nile virus? While most people infected with the virus do not feel sick, about one in five will develop a fever and flu-like symptoms. Other symptoms include body aches, vomiting, diarrhea, or rash. Severe illness can occur in about one in 150 people and is most likely to occur in people over age 55 or with weakened immune systems. The department said there are no specific medications to treat the virus in people. The best way to prevent getting sick is to prevent mosquito bites.
Business Wire
2 days ago
- Business Wire
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the monthly attack rate (92% mean and 97% median). These results further support navenibart's favorable safety and tolerability profile, and potential every three- (Q3M) and every six-month (Q6M) dosing regimens. 'We are thrilled to share positive initial results from the ALPHA-SOLAR long-term open-label trial,' said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. 'Results are consistent with navenibart's best-in-class profile that we saw in the ALPHA-STAR Phase 1b/2 trial. With now 12 to 18 months on navenibart, these ALPHA-SOLAR results support navenibart's favorable profile and the potential to administer navenibart every 3 and every 6 months. The Phase 3 ALPHA-ORBIT trial is evaluating both every 3- and every 6-month regimens and is actively enrolling patients. Navenibart's profile and results that we have seen to date demonstrate the potential for navenibart to be the market-leading HAE therapy.' 'The navenibart results in patients to date support the potential for patients to have long-acting protection from their HAE attacks with very low treatment burden,' said Dr. William Yang, M.D., PRCPC, FAAAAI, Chair, Ottawa Allergy Research Corporation and Red Maple Trials Inc. 'We are excited for the Phase 3 ALPHA-ORBIT trial and believe that navenibart's profile with infrequent dosing could allow patients to spend less time thinking about their HAE, and more time living their lives.' ALPHA-SOLAR is a long-term open-label trial in adults with HAE Type 1 or 2 designed to assess long-term safety and efficacy of navenibart. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial elected to enroll in ALPHA-SOLAR. ALPHA-STAR patients from Cohorts 1 and 2 enrolled in Arm A, and ALPHA-STAR patients from Cohort 3 enrolled in Arm B (described in the table below). Initial results from ALPHA-SOLAR 1: Comparisons to baseline from ALPHA-STAR. Navenibart demonstrated overall attack-freedom of 50% over six months, which is the longest period of follow-up for all 16 patients to date. All patients remain in the ALPHA-SOLAR trial. Navenibart was well-tolerated with no severe or serious treatment-emergent adverse events (TEAEs) and no discontinuations. One participant experienced two treatment-related, mild injection site reactions that resolved without treatment. There were no injection site reactions of pain. The safety profile of navenibart in patients with HAE was favorable through more than 17 months (median / mean) of cumulative follow-up since the initiation of navenibart in ALPHA-STAR. The results shared above are available in a poster presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress on June 13, 2025. The poster is accessible to conference attendees and also in the Scientific Presentations and Publications section of In February 2025, Astria initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is evaluating navenibart administered Q3M and Q6M and currently enrolling patients. For more information, visit NCT06842823 or About Navenibart: Navenibart is a monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of HAE. Our goal with navenibart is to provide rapid and sustained HAE attack prevention with a validated mechanism and trusted modality administered subcutaneously every 3 and 6 months. We aim to empower people living with HAE to live life without limitations from their disease. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the results from the navenibart Phase 1b/2 ALPHA-STAR clinical trial and initial results from the ALPHA-SOLAR trial; the goals and objectives of the ALPHA-ORBIT trial; the potential therapeutic benefits of navenibart as a treatment for HAE; the potential attributes and profile of navenibart as a treatment for HAE, including its potential to be a life-changing, market leading preventative treatment for HAE, and our overall vision and goals for the navenibart program; and our corporate strategy and vision, including our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goals,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be replicated in clinical trials, that the preliminary, initial or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the ALPHA-STAR Phase 1b/2 clinical trial, may not be replicated in later stage clinical trials, such as the planned Phase 3 development program, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the U.S. Food and Drug Administration and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to navenibart, STAR-0310, and any other future development candidates; our ability to manufacture sufficient quantities of drug substance and drug product for navenibart, STAR-0310, and any other future product candidates on a cost-effective and timely basis, and to develop dosages and formulations for navenibart, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefor; our ability to obtain, maintain and enforce intellectual property rights for navenibart, STAR-0310 and any other future product candidates; our potential dependence on collaboration partners; competition with respect to navenibart, STAR-0310, or any of our other future product candidates; the risk that survey results, modeling data and market research may not be accurate predictors of the commercial landscape for HAE, the ability of navenibart to compete in HAE and the anticipated position and attributes of navenibart in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks that any of our clinical trials of STAR-0310 may not commence, continue or be completed on time, or at all; risks that results of preclinical studies of STAR-0310 will not be replicated in clinical trials; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the 'Risk Factors' section of our Annual Report on Form 10-K for the period ended December 31, 2024 and in other filings that we may make with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof.
Yahoo
2 days ago
- Yahoo
From heartbreak to hope; suicide loss survivor says 'You are not alone'
FARMERSBURG, Ind. (WTWO/WAWV) — According to the CDC in 2023, suicide was the second leading cause of death among those ages 10 to 34. Losing a loved one to suicide is a pain that's nearly impossible to put into words. But in Sullivan County, one couple is doing just that—finding the words, sharing their story, and helping others find hope again. It's a mission born out of heartbreak and now, healing. On the county road next to Westlawn Cemetery in Farmersburg, Mike Frey spins the tires against the pavement in the truck he and his son, Cade, once restored together. They call them 'Burnouts for Cade.' A cloud of smoke. A roar of horsepower. A father's way of saying, I love you, I miss you. 'It has helped us grieve'; loved ones share the silver lining of organ donation after loss 'Cade was my son,' Mike said. 'He passed away from suicide, November 24, 2020. He had just graduated from high school at Sullivan. An amazing young man, he was a race car driver at the quarter midget track in Terre Haute, he loved motocross, he loved making people laugh and smile more.' Mike went on to describe his last interactions with his son and talked about the plans he had for the year. 'We did not see this coming,' he said as a silence fell over him. 'No one saw this coming.' Cade Frey took his life the Tuesday before Thanksgiving. 'I remember that day when I found him,' Mike said. 'There was nothing else we could've done for Cade,' Mike said as he was overcome with emotion. 'There was just nothing they could do.' Cade's organs were donated, and he saved five lives. But his absence left a void that Mike and his companion Rebecca are still learning to live with. 'I go by every single morning, by the graveside, and tell my son good morning, and try to go by every single evening and tell him goodnight,' Mike said. Their journey led them to Team of Mercy, a nonprofit based in Terre Haute that helps those left behind after losing a loved one to suicide. Snow angels made to honor life of Sullivan High School student 'We went to our first meeting in Terre Haute and have been going ever since for the last five years, every month,' he said. The couple now leads Team of Mercy's monthly survivor support group in Sullivan. 'It's just a place we can connect with others in Sullivan who are going through the same thing we are,' Mike said. 'Being around people who have experienced what you've gone through and what you've lost is very, very important because then you realize that you aren't alone, that you are sharing this with other people,' Rebecca said. 'I honestly feel if we didn't have Team of Mercy helping us through all of this, I'm not so sure we would get out of bed some days,' she added. Christina Crist knows that pain all too well. She lost her daughter Hannah to suicide in 2013 and became one of the driving forces behind Team of Mercy. 'Hannah, at the time of her death, was 15 years old, a sophomore at South High School. It had rocked our community's world to know that a 15-year-old, let alone thought about suicide, but actually took her life,' Christna said. Christina described Hannah as tears filled her eyes, 'A fun-loving kid. Charismatic, loving, caring,' she said. 'Kids described her as someone who, if they would be having a bad day and Hannah would notice that and do whatever she could to make sure they were going to have a better day.' A decade later, Christina's grief hasn't faded — but it has evolved. And through her pain, she's found a purpose. 'You will never ever, ever get over this,' Christina said. 'You're not supposed to. But what we learn to do is live in it. We learn to thrive in it, we learn to go on, we figure out how to still hold a piece of our loved ones.' For Christina, it's white butterflies. She spotted one when she sat down for this interview. She said the butterflies may have always been there, but it was after her daughter's death that she started noticing them. 'For almost 13 years, my other daughter and I, whenever we see a white butterfly, we say 'Hi Hannah.' Do I really think that's Hannah in that butterfly?' she questioned. 'No. No. But we find ways to bring joy in such absolute gut-wrenching pain. And if it's a white butterfly, 'Hi Hannah, hi.' And with every story shared—every burnout, every butterfly, every meeting—these survivors are making sure that their loved ones' stories never fade. 'I've lost my son, I can't feel any worse than I do,' Mike says as he chokes up. He takes a moment and then continues. 'There is nothing you could do to me to make me feel any worse after losing him. But if I could help one family from feeling that way, another family, that's all I want,' he added. As the white smoke from the burnout rises across the cemetery and over Cade's gravestone, so does Mike's message, 'You are not alone.' If you've lost a loved one to suicide, Team of Mercy wants you to know that you don't have to walk that journey alone. Mike and Rebecca host the Suicide Loss Support Group in Sullivan on the third Monday of each month from 6:00 p.m. until 8:00 p.m. at Abundant Grace Church. It's located at 671 W Wolfe St., behind Walmart in Sullivan. The next meeting is happening on Monday, June 16. For more information on Team of Mercy, click here. If you are experiencing mental health-related distress or are worried about a loved one who may need crisis support, contact the 988 Suicide and Crisis Lifeline by clicking here. You can also text or call the hotline by dialing 988. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
